1. Home
  2. CSBR vs CING Comparison

CSBR vs CING Comparison

Compare CSBR & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Champions Oncology Inc.

CSBR

Champions Oncology Inc.

N/A

Current Price

$4.75

Market Cap

65.4M

Sector

Health Care

ML Signal

N/A

CING

Cingulate Inc.

N/A

Current Price

$4.32

Market Cap

70.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CSBR
CING
Founded
1985
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.4M
70.2M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
CSBR
CING
Price
$4.75
$4.32
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $21.20
AVG Volume (30 Days)
6.8K
★ 114.5K
Earning Date
12-14-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 56.47
EPS
★ N/A
N/A
Revenue
★ $2,900,000.00
N/A
Revenue This Year
$9.83
N/A
Revenue Next Year
$8.50
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.59
$3.16
52 Week High
$8.31
$11.89

Technical Indicators

Market Signals
Indicator
CSBR
CING
Relative Strength Index (RSI) 46.04 36.16
Support Level $4.71 $4.19
Resistance Level $5.17 $5.31
Average True Range (ATR) 0.21 0.31
MACD 0.01 -0.07
Stochastic Oscillator 29.84 3.50

Price Performance

Historical Comparison
CSBR
CING

About CSBR Champions Oncology Inc.

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: